Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.75+0.04 (+1.08%)
Close on Nov 17, 2026Market cap $286.12MP/E –Yield –
Fulcrum Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Fulcrum Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$65.78M. For fiscal 2025 it was -$60.07M. The highest annual figure on record is -$2.22M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.07M | – |
| FY2024 | Dec 31, 2024 | -$2.22M | – |
| FY2023 | Dec 31, 2023 | -$90.97M | – |
| FY2022 | Dec 31, 2022 | -$97.05M | – |
| FY2021 | Dec 31, 2021 | -$78.48M | – |
| FY2020 | Dec 31, 2020 | -$53.66M | – |
| FY2019 | Dec 31, 2019 | -$39.48M | – |
| FY2018 | Dec 31, 2018 | -$22.56M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.82M | -123.5% |
| Q1 FY2025 | Mar 31, 2025 | -$15.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.76M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.07M | – |
| Q2 FY2024 | Jun 30, 2024 | $58.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.57M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.02M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.07M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.90M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.40M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.12M | – |
See a number that looks wrong?